Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN vs ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin and thromboxane synthesis, which leads to analgesic, antipyretic, and anti-inflammatory effects.
Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Migraine pain relief,Headache,Muscle aches,Menstrual cramps,Arthritis,Reduction of risk of myocardial infarction (low-dose)
Mild to moderate pain,Fever (acetaminophen and aspirin),Inflammatory conditions (aspirin)
500-1000 mg orally every 4-6 hours as needed; maximum 4000 mg in 24 hours.
1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.
Aspirin half-life is 15-20 minutes due to rapid hydrolysis to salicylate. Salicylate terminal half-life is 2-3 hours at low doses, up to 15-30 hours at high doses or with toxicity. At analgesic doses (600-1000 mg), effective half-life is ~3-4 hours, requiring q4-6h dosing.
Acetaminophen: 2-3 hours (terminal). Aspirin: 15-30 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable metabolism. Codeine: 2.5-4 hours. Clinical context: Prolonged half-life of salicylate at high doses increases risk of toxicity; hepatic impairment prolongs acetaminophen and codeine half-lives.
Primarily metabolized by hepatic esterases to salicylate; conjugation with glycine (salicyluric acid) and glucuronic acid (salicyl phenolic glucuronide) mainly in the liver; also metabolized by cytochrome P450 (CYP) enzymes (CYP2C9) to a lesser extent.
Acetaminophen: hepatic via CYP2E1, CYP1A2, CYP3A4; glucuronidation and sulfation; NAPQI formation. Aspirin: hepatic hydrolysis to salicylate; conjugation with glycine and glucuronic acid. Codeine: hepatic via CYP2D6 to morphine (active); also via CYP3A4 to norcodeine.
Renal excretion of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid). Approximately 90% of a dose is excreted renally; 10% via bile/feces. Excretion is dose- and p H-dependent: alkaline urine increases clearance.
Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates, ~85-90%), minor parent drug (<5%). Aspirin: renal excretion of salicylate and its metabolites (salicyluric acid, glucuronides, gentisic acid), dose-dependent; at therapeutic doses, ~50-80% as free salicylate and conjugates. Codeine: renal excretion of free and conjugated codeine (about 90%) and metabolites (morphine, norcodeine).
80-90% bound to serum albumin, primarily binding site I (warfarin site). Binding is saturable and decreases at high concentrations, increasing free fraction and toxicity risk.
Acetaminophen: 10-25% (albumin). Aspirin: 50-80% (albumin), dose-dependent; salicylate: 75-90% (albumin). Codeine: ~7% (albumin).
0.15-0.2 L/kg for aspirin; for salicylate 0.1-0.2 L/kg. Low Vd reflects limited extravascular distribution; does not extensively penetrate brain except at high doses (therapeutic for migraine likely CNS penetration via passive diffusion).
Acetaminophen: 0.9-1.0 L/kg (large distribution including liver). Aspirin: 0.15-0.2 L/kg (low Vd, confined to plasma and extracellular fluid); salicylate: 0.2-0.3 L/kg. Codeine: 3-6 L/kg (extensive tissue distribution). Clinical meaning: Large Vd for codeine suggests extensive tissue binding; aspirin Vd is small, consistent with limited extravascular distribution.
Oral immediate-release aspirin: 50-75% (due to first-pass hydrolysis in GI mucosa and liver). Enteric-coated: reduced and delayed absorption. Rectal: 20-50% (variable). For BAYER EXTRA STRENGTH ASPIRIN (500 mg), ~60% bioavailability.
Oral: Acetaminophen: 85-95%. Aspirin: 40-60% (due to first-pass hydrolysis to salicylate). Codeine: ~50% due to first-pass metabolism.
GFR 10-50 m L/min: avoid or reduce dose to 500 mg every 6 hours; GFR <10 m L/min: contraindicated.
GFR 30-59 m L/min: Administer every 6 hours; maximum 6 tablets/day. GFR 15-29 m L/min: Administer every 12 hours; maximum 4 tablets/day. GFR <15 m L/min: Not recommended due to accumulation of codeine metabolites.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% or extend interval to 8 hours; Class C: contraindicated.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and extend interval to every 6 hours; maximum 4 tablets/day. Child-Pugh Class C: Contraindicated.
Weight <40 kg: 10-15 mg/kg orally every 4-6 hours, maximum 60 mg/kg/day; Weight ≥40 kg: adult dosing.
Not recommended for children <12 years due to aspirin risk of Reye syndrome. For children ≥12 years: Dose based on codeine component (0.5-1 mg/kg/dose) with maximum acetaminophen 75 mg/kg/day and aspirin 100 mg/kg/day. Typical: 1 tablet (acetaminophen 300 mg/aspirin 300 mg/codeine 30 mg) every 4-6 hours as needed; max 4 tablets/day.
Start at lowest effective dose (500 mg every 6-8 hours); monitor renal function and bleeding risk.
Start with lowest effective dose (e.g., 1 tablet every 6 hours); monitor renal and hepatic function; maximum 6 tablets/day due to increased sensitivity and risk of adverse effects.
Reye's syndrome: Aspirin should not be used in children or teenagers with viral infections due to risk of Reye's syndrome.
Risk of medication errors: confusion between different strengths and concentrations of acetaminophen can result in accidental overdose and fatal hepatotoxicity. Aspirin use in children and teenagers with viral infections is associated with Reye's syndrome.
Increased risk of gastrointestinal bleeding, ulcers, and perforation; hypersensitivity reactions including anaphylaxis; increased bleeding risk; severe hepatic injury; caution in patients with asthma, G6PD deficiency, renal impairment, or history of peptic ulcer disease.
Hepatotoxicity (acetaminophen dose >4 g/day), Reye's syndrome (aspirin in children), respiratory depression (codeine), tolerance/dependence, bleeding risk (aspirin), GI toxicity, renal impairment, hypersensitivity reactions.
Hypersensitivity to aspirin or NSAIDs; active peptic ulcer disease; severe hepatic or renal impairment; bleeding disorders; patients with viral infections (children/teenagers) due to Reye's syndrome risk; third trimester of pregnancy.
Hypersensitivity to any component, active peptic ulcer disease, bleeding disorders, severe hepatic impairment, severe respiratory depression, children with viral illness (aspirin), pregnancy (third trimester for aspirin, codeine cautious).
High-fat meals may delay absorption and reduce efficacy. Avoid alcohol to minimize GI bleeding risk. No significant food interactions beyond general GI irritation, but taking with food may improve tolerance.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and aspirin-induced GI bleeding. Avoid large amounts of caffeine or high-tyramine foods (e.g., aged cheeses, cured meats) as they may affect CYP2D6 metabolism of codeine.
First trimester: Epidemiologic studies suggest an increased risk of gastroschisis and possibly other congenital anomalies with use, though absolute risk is low. Second trimester: Avoid due to potential effects on fetal renal function and premature closure of ductus arteriosus, though risk is lower than third trimester. Third trimester: Contraindicated. Use in third trimester increases risk of premature closure of ductus arteriosus, oligohydramnios, and periventricular hemorrhage in the fetus; may prolong gestation and labor.
Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastroschisis; second trimester: relatively safe; third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, and increased peripartum hemorrhage. Codeine: First trimester: possible neural tube defects; second and third trimesters: risk of respiratory depression, withdrawal in neonate with chronic use; neonatal opioid withdrawal syndrome (NOWS) possible.
Aspirin (acetylsalicylic acid) is excreted into breast milk in low concentrations. Milk-to-plasma ratio (M/P) is approximately 0.03-0.11 for salicylate. No adverse effects in breastfeeding infants have been reported with occasional low doses. However, regular high-dose use may lead to accumulation and potential toxicity in the infant (e.g., Reye's syndrome). Avoid use during breastfeeding; if needed, use lowest effective dose and monitor infant for bruising, bleeding, or metabolic acidosis.
Acetaminophen: M/P ratio approximately 0.91-1.42; considered safe. Aspirin: M/P ratio 0.08-0.15; high doses may cause Reye's syndrome; avoid or use low doses. Codeine: M/P ratio about 2.5; variable metabolism; risk of CNS depression in infant; avoid due to potential for toxicity in CYP2D6 ultrarapid metabolizers.
Aspirin pharmacokinetics in pregnancy: Increased renal clearance and plasma volume may lower salicylate concentrations. However, due to teratogenic risks, routine aspirin use is not recommended. For specific indications (e.g., preeclampsia prevention, antiphospholipid syndrome), low-dose aspirin (81 mg/day) is used without dose adjustment. For high-dose or anti-inflammatory doses (e.g., 650 mg every 4-6 hours), avoid entirely in pregnancy, especially in third trimester.
Acetaminophen: No dose adjustment needed. Aspirin: Avoid in third trimester; use lowest effective dose if necessary. Codeine: Avoid in pregnancy; if used, lowest effective dose for shortest duration; caution for CYP2D6 polymorphism. Pharmacokinetic changes: Increased clearance of codeine during pregnancy may require higher doses but risk outweighs benefit.
For migraine pain, aspirin 500-1000 mg (equivalent to 2-4 tablets of Bayer Extra Strength) is recommended at onset. Note that aspirin is contraindicated in patients with a history of nasal polyps, angioedema, or bronchospasm with NSAIDs. Monitor for tinnitus or hearing loss as signs of salicylate toxicity. Avoid use within 48 hours of alcohol cessation therapy due to GI irritation.
Combination analgesic with acetaminophen (hepatotoxic at high doses), aspirin (antiplatelet, GI irritant, contraindicated in children <12 due to Reye's syndrome), and codeine (prodrug to morphine via CYP2D6; efficacy depends on CYP2D6 phenotype; risk of CNS/respiratory depression). Avoid in severe hepatic/renal impairment, active peptic ulcer, bleeding disorders, or concomitant use of other CNS depressants. Maximum acetaminophen dose from all sources: 4 g/day.
Take this medication at the first sign of migraine pain for best results.,Do not exceed 8 tablets (4000 mg aspirin) in 24 hours.,Avoid alcohol while taking aspirin to reduce risk of stomach bleeding.,Do not use if you have a history of stomach ulcers, bleeding disorders, or asthma triggered by aspirin.,Consult a doctor if your migraine does not improve after 1-2 doses or if you have severe symptoms.,Keep out of reach of children; Reye's syndrome warning if given to children or teenagers with viral illness.
Do not exceed recommended dose; acetaminophen overdosage can cause serious liver damage.,Do not take with other products containing acetaminophen or aspirin.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,This product contains aspirin; do not give to children/teenagers with chickenpox or flu-like symptoms to avoid Reye's syndrome.,May cause drowsiness; do not drive or operate machinery until you know how you react.,Codeine is a narcotic pain reliever with abuse potential; use exactly as prescribed.,Seek medical attention if you experience signs of allergic reaction (rash, difficulty breathing) or bleeding (black/tarry stools, unusual bruising).
No interactions on record
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN vs ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, answered by our medical review team.
BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN is a NSAID / Antiplatelet that works by Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin and thromboxane synthesis, which leads to analgesic, antipyretic, and anti-inflammatory effects.. ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN and ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN is: 500-1000 mg orally every 4-6 hours as needed; maximum 4000 mg in 24 hours.. The standard adult dose of ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is: 1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN and ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN is classified as Category D/X. First trimester: Epidemiologic studies suggest an increased risk of gastroschisis and possibly other congenital anomalies with use, though absolute risk is low. Second trimester: A. ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastrosch. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.